ERBB2 and breast carcinoma: Furthermore, a (HER2)2xCD16 tribody form, which comprises two HER2-specific single chain fragment variable fused to a fragment antigen binding to the CD16 expressed on γδ T or NK cells, enhanced the anti-tumor activity of γδ T and NK cells against HER2-expressing tumors, including pancreatic cancer, breast cancer and ovarian cancer [117].